Welcome to the BioLogicTube jeo@biologicmedia.dk https://biologictube.dk/app/facebook en-us Visualplatform http://blogs.law.harvard.edu/tech/rss Welcome to the BioLogicTube episodic no https://biologictube.dk/app/facebook/files/rv0.0/sitelogo.gif https://biologictube.dk/app/facebook http://biologictube.dk/photo/3088338/supar-og-autoimmun-sygdom-folketinget <p>Jesper Eugen-Olsen talks on autoimmunity and immune activation at the Danish Parliament 2009<br></p><p><a href="http://biologictube.dk/photo/3088338/supar-og-autoimmun-sygdom-folketinget"><img src="http://biologictube.dk/1984077/3088338/09970fcdde001cd8ee1a345405947289/standard/download-1-thumbnail.jpg" width="600" height="337"/></a></p> http://biologictube.dk/photo/3088338 Tue, 21 May 2013 15:51:32 GMT suPAR og autoimmun sygdom - Folketinget 2009 Jesper Eugen-Olsen talks on autoimmunity and immune activation at the Danish Parliament 2009 Jesper Eugen-Olsen talks on autoimmunity and immune activation at the Danish Parliament 2009 Welcome to the BioLogicTube 05:00 <p>Jesper Eugen-Olsen talks on autoimmunity and immune activation at the Danish Parliament 2009<br></p><p><a href="http://biologictube.dk/photo/3088338/supar-og-autoimmun-sygdom-folketinget"><img src="http://biologictube.dk/1984077/3088338/09970fcdde001cd8ee1a345405947289/standard/download-1-thumbnail.jpg" width="600" height="337"/></a></p> - 2009 eugen-olsen folketinget jesper http://biologictube.dk/photo/4959161/brain-prize-winners-2012-karen <p>The Grete Lundbeck European Brain Research Foundation has announced that The Brain Prize 2012 is jointly awarded to Christine Petit and Karen Steel:<br /> ‘for their unique, world-leading contributions to our understanding of the genetic regulation of the development and functioning of the ear, and for elucidating the causes of many of the hundreds of inherited forms of deafness’.<br /> Inherited conditions render one in a thousand children deaf at birth, and cause as many again to become deaf before maturity, leading to delay or failure in the acquisition of speech, and frequently to disadvantages in communication and learning. Genetic anomalies also contribute to many age-related and progressive forms of hearing loss. About one-tenth of the population in the developed world suffers from significant hearing impairment, which has an enormous impact on individuals and on society.<br /> Karen Steel and Christine Petit are at the forefront of efforts to understand the molecular mechanisms of the specialised hair cells in the inner ear, whose extraordinary sensitivity to mechanical stimulation underpins the senses of hearing and balance. These two researchers, at the peak of their productivity and influence, are international leaders in the field of hereditary deafness.<br /> Each has brought special skill to this challenging area of research. Their approaches have been complementary. Karen Steel has worked upwards, employing elegant and exhaustive study of mutations in mice and their functional consequences to illuminate human disorders. Christine Petit has started with the genetic analysis of patients, subsequently investigating the role of the identified genes in animal model systems.<br /> Professor Colin Blakemore, Oxford University, Chairman of the Selection Committee said: ‘Together, the work of these two Europeans scientists illustrates the value and power of interdisciplinary approaches in neuroscience, and the way in which cutting-edge fundamental research is needed to understand complex clinical problems and to accelerate benefit for patients’.......’We are delighted that The Brain Prize for the best of European neuroscience goes, in its second year, to two<br /> Ole Maaløes Vej 3 DK-2200 Copenhagen N Denmark<br /> Tel. +45 3917 8240 <a href="mailto:info@thebrainprize.org">info@thebrainprize.org</a> www.thebrainprize.org<br /> 12 March 2012<br /> women scientists. We are sure that the award will be applauded by female researchers around the world, and by all those who are concerned that young women are given every encouragement to consider careers in science’<br /> The prize lectures and award ceremony will take place 9th May in Copenhagen, Denmark. The Prize will be presented by Her Majesty the Queen.<br /> Bios: Christine Petit, Professor at College de France, holding the Chair of Genetics and Cellular Physiology, head of the Genetics and Physiology of Hearing laboratory at the Institut Pasteur in Paris also affiliated to INSERM, is a geneticist and a neurobiologist. She conceived and pioneered the genetic strategy to assess the molecular mechanisms underlying the cochlear differentiation and physiology. She developed this genetic approach in humans, by succeeding to overcome the difficulties specific to linkage analysis for deafness. She thereby mapped to human chromosomes the first two genes responsible for hereditary congenital deafness. She identified the causative genes for about 20 inherited forms of deafness, initially by an innovative candidate gene approach. Together with her colleagues, she also unraveled the roles of most of the proteins encoded by these genes, namely in the sensory hair cells, their stimulating gel, and the supporting cells, by multidisciplinary studies of engineered mouse models. Her work shed light on the functions mediated through various fibrous links within the hair bundle, the mechanoreceptive structure to sound. Her work on Usher syndrome (deafness, blindness), demonstrated that all Usher 1 proteins as well as all Usher 2 proteins form protein networks enabling the links they form to shape the hair bundle. She also identified some Usher1 proteins as components of the mechanotransduction machinery. Christine Petit’s discoveries have already had a significant impact on medical practice, with respect to diagnosis, genetic counseling and therapeutic decisions by indicating the potential benefit of cochlear implants and hearing aids for patients.<br /> Karen Steel, Professor and Principal Investigator for the Genetics of Deafness and founder of the Mouse Genetics Programme at the Wellcome Trust Sanger Institute, Hinxton, near Cambridge, UK, has pioneered the use of mouse models, starting with her painstaking description of the characteristics of mutant mice with disorders of balance and hearing. Her early work on cochlear function and hair cell degeneration in the mutant deafness mouse led to identification of the gene called Tmc1, the human homologue of which is mutated in several forms of hereditary deafness. She and her colleagues went on to identify causative genes in nearly 30 forms of hearing disorder in mice, most of which have been linked to human conditions. In particular, she described the genes for myosin-7a and cadherin-23, which are key components in the transduction mechanism in hair cells, and mutations of which underlie forms of Usher Syndrome. Karen Steel is internationally recognized for her generous and altruistic approach to science. Working with a consortium of European researchers, she has established, catalogued and made freely available to other researchers<br /> several hundred mouse mutant lines, which have facilitated research in several areas of neuroscience around the world.<br /> About the Brain Prize The Brain Prize - € 1 million is awarded by Grete Lundbeck European Brain Research Foundation, a charitable, non-profit organization.<br /> The Brain Prize is a personal prize awarded to one or more scientists who have distinguished themselves by an outstanding contribution to European neuroscience.<br /> For more information please contact:<br /> Kim Krogsgaard, MD, DMSc or Director Mobile: +45 2014 8384 Phone: +45 3917 8240 <a href="mailto:kk@thebrainprize.org">kk@thebrainprize.org</a><br /> Nils Axelsen, MD, DMsc Chairman Mobile: +45 40548646<br /> Grete Lundbeck European Brain Research Foundation Ole Maaløes Vej 3 2200 N Copenhagen<br /> Denmark<br /> www.thebrainprize.org</p><p><a href="http://biologictube.dk/photo/4959161/brain-prize-winners-2012-karen"><img src="http://biologictube.dk/4959050/4959161/221a778e8530641df57b207fd7d2b4ab/standard/download-1-thumbnail.jpg" width="600" height="338"/></a></p> http://biologictube.dk/photo/4959161 Sun, 06 May 2012 13:44:37 GMT Brain Prize Winners 2012 Karen Steel and Christine Petit The Grete Lundbeck European Brain Research Foundation has announced that The Brain Prize 2012 is jointly awarded to Christine Petit and Karen Steel: ‘for their unique, world-leading contributions to our understanding of the genetic regulation of the development and functioning of the ear, and for elucidating the causes of many of the hundreds of inherited forms of deafness’. Inherited conditions render one in a thousand children deaf at birth, and cause as many again to become deaf before maturity, leading to delay or failure in the acquisition of speech, and frequently to disadvantages in communication and learning. Genetic anomalies also contribute to many age-related and progressive forms of hearing loss. About one-tenth of the population in the developed world suffers from significant hearing impairment, which has an enormous impact on individuals and on society. Karen Steel and Christine Petit are at the forefront of efforts to understand the molecular mechanisms of the specialised hair cells in the inner ear, whose extraordinary sensitivity to mechanical stimulation underpins the senses of hearing and balance. These two researchers, at the peak of their productivity and influence, are international leaders in the field of hereditary deafness. Each has brought special skill to this challenging area of research. Their approaches have been complementary. Karen Steel has worked upwards, employing elegant and exhaustive study of mutations in mice and their functional consequences to illuminate human disorders. Christine Petit has started with the genetic analysis of patients, subsequently investigating the role of the identified genes in animal model systems. Professor Colin Blakemore, Oxford University, Chairman of the Selection Committee said: ‘Together, the work of these two Europeans scientists illustrates the value and power of interdisciplinary approaches in neuroscience, and the way in which cutting-edge fundamental research is needed to understand complex clinical problems and to accelerate benefit for patients’.......’We are delighted that The Brain Prize for the best of European neuroscience goes, in its second year, to two Ole Maaløes Vej 3 DK-2200 Copenhagen N Denmark Tel. +45 3917 8240 info@thebrainprize.org www.thebrainprize.org 12 March 2012 women scientists. We are sure that the award will be applauded by female researchers around the world, and by all those who are concerned that young women are given every encouragement to consider careers in science’ The prize lectures and award ceremony will take place 9th May in Copenhagen, Denmark. The Prize will be presented by Her Majesty the Queen. Bios: Christine Petit, Professor at College de France, holding the Chair of Genetics and Cellular Physiology, head of the Genetics and Physiology of Hearing laboratory at the Institut Pasteur in Paris also affiliated to INSERM, is a geneticist and a neurobiologist. She conceived and pioneered the genetic strategy to assess the molecular mechanisms underlying the cochlear differentiation and physiology. She developed this genetic approach in humans, by succeeding to overcome the difficulties specific to linkage analysis for deafness. She thereby mapped to human chromosomes the first two genes responsible for hereditary congenital deafness. She identified the causative genes for about 20 inherited forms of deafness, initially by an innovative candidate gene approach. Together with her colleagues, she also unraveled the roles of most of the proteins encoded by these genes, namely in the sensory hair cells, their stimulating gel, and the supporting cells, by multidisciplinary studies of engineered mouse models. Her work shed light on the functions mediated through various fibrous links within the hair bundle, the mechanoreceptive structure to sound. Her work on Usher syndrome (deafness, blindness), demonstrated that all Usher 1 proteins as well as all Usher 2 proteins form protein networks enabling the links they form to shape the hair bundle. She also identified some Usher1 proteins as components of the mechanotransduction machinery. Christine Petit’s discoveries have already had a significant impact on medical practice, with respect to diagnosis, genetic counseling and therapeutic decisions by indicating the potential benefit of cochlear implants and hearing aids for patients. Karen Steel, Professor and Principal Investigator for the Genetics of Deafness and founder of the Mouse Genetics Programme at the Wellcome Trust Sanger Institute, Hinxton, near Cambridge, UK, has pioneered the use of mouse models, starting with her painstaking description of the characteristics of mutant mice with disorders of balance and hearing. Her early work on cochlear function and hair cell degeneration in the mutant deafness mouse led to identification of the gene called Tmc1, the human homologue of which is mutated in several forms of hereditary deafness. She and her colleagues went on to identify causative genes in nearly 30 forms of hearing disorder in mice, most of which have been linked to human conditions. In particular, she described the genes for myosin-7a and cadherin-23, which are key components in the transduction mechanism in hair cells, and mutations of which underlie forms of Usher Syndrome. Karen Steel is internationally recognized for her generous and altruistic approach to science. Working with a consortium of European researchers, she has established, catalogued and made freely available to other researchers several hundred mouse mutant lines, which have facilitated research in several areas of neuroscience around the world. About the Brain Prize The Brain Prize - € 1 million is awarded by Grete Lundbeck European Brain Research Foundation, a charitable, non-profit organization. The Brain Prize is a personal prize awarded to one or more scientists who have distinguished themselves by an outstanding contribution to European neuroscience. For more information please contact: Kim Krogsgaard, MD, DMSc or Director Mobile: +45 2014 8384 Phone: +45 3917 8240 kk@thebrainprize.org Nils Axelsen, MD, DMsc Chairman Mobile: +45 40548646 Grete Lundbeck European Brain Research Foundation Ole Maaløes Vej 3 2200 N Copenhagen Denmark www.thebrainprize.org The Grete Lundbeck European Brain Research Foundation has announced that The Brain Prize 2012 is jointly awarded to Christine Petit and Karen Steel: ‘for their unique, world-leading contributions to our understanding of the genetic regulation of... Welcome to the BioLogicTube 03:28 <p>The Grete Lundbeck European Brain Research Foundation has announced that The Brain Prize 2012 is jointly awarded to Christine Petit and Karen Steel:<br /> ‘for their unique, world-leading contributions to our understanding of the genetic regulation of the development and functioning of the ear, and for elucidating the causes of many of the hundreds of inherited forms of deafness’.<br /> Inherited conditions render one in a thousand children deaf at birth, and cause as many again to become deaf before maturity, leading to delay or failure in the acquisition of speech, and frequently to disadvantages in communication and learning. Genetic anomalies also contribute to many age-related and progressive forms of hearing loss. About one-tenth of the population in the developed world suffers from significant hearing impairment, which has an enormous impact on individuals and on society.<br /> Karen Steel and Christine Petit are at the forefront of efforts to understand the molecular mechanisms of the specialised hair cells in the inner ear, whose extraordinary sensitivity to mechanical stimulation underpins the senses of hearing and balance. These two researchers, at the peak of their productivity and influence, are international leaders in the field of hereditary deafness.<br /> Each has brought special skill to this challenging area of research. Their approaches have been complementary. Karen Steel has worked upwards, employing elegant and exhaustive study of mutations in mice and their functional consequences to illuminate human disorders. Christine Petit has started with the genetic analysis of patients, subsequently investigating the role of the identified genes in animal model systems.<br /> Professor Colin Blakemore, Oxford University, Chairman of the Selection Committee said: ‘Together, the work of these two Europeans scientists illustrates the value and power of interdisciplinary approaches in neuroscience, and the way in which cutting-edge fundamental research is needed to understand complex clinical problems and to accelerate benefit for patients’.......’We are delighted that The Brain Prize for the best of European neuroscience goes, in its second year, to two<br /> Ole Maaløes Vej 3 DK-2200 Copenhagen N Denmark<br /> Tel. +45 3917 8240 <a href="mailto:info@thebrainprize.org">info@thebrainprize.org</a> www.thebrainprize.org<br /> 12 March 2012<br /> women scientists. We are sure that the award will be applauded by female researchers around the world, and by all those who are concerned that young women are given every encouragement to consider careers in science’<br /> The prize lectures and award ceremony will take place 9th May in Copenhagen, Denmark. The Prize will be presented by Her Majesty the Queen.<br /> Bios: Christine Petit, Professor at College de France, holding the Chair of Genetics and Cellular Physiology, head of the Genetics and Physiology of Hearing laboratory at the Institut Pasteur in Paris also affiliated to INSERM, is a geneticist and a neurobiologist. She conceived and pioneered the genetic strategy to assess the molecular mechanisms underlying the cochlear differentiation and physiology. She developed this genetic approach in humans, by succeeding to overcome the difficulties specific to linkage analysis for deafness. She thereby mapped to human chromosomes the first two genes responsible for hereditary congenital deafness. She identified the causative genes for about 20 inherited forms of deafness, initially by an innovative candidate gene approach. Together with her colleagues, she also unraveled the roles of most of the proteins encoded by these genes, namely in the sensory hair cells, their stimulating gel, and the supporting cells, by multidisciplinary studies of engineered mouse models. Her work shed light on the functions mediated through various fibrous links within the hair bundle, the mechanoreceptive structure to sound. Her work on Usher syndrome (deafness, blindness), demonstrated that all Usher 1 proteins as well as all Usher 2 proteins form protein networks enabling the links they form to shape the hair bundle. She also identified some Usher1 proteins as components of the mechanotransduction machinery. Christine Petit’s discoveries have already had a significant impact on medical practice, with respect to diagnosis, genetic counseling and therapeutic decisions by indicating the potential benefit of cochlear implants and hearing aids for patients.<br /> Karen Steel, Professor and Principal Investigator for the Genetics of Deafness and founder of the Mouse Genetics Programme at the Wellcome Trust Sanger Institute, Hinxton, near Cambridge, UK, has pioneered the use of mouse models, starting with her painstaking description of the characteristics of mutant mice with disorders of balance and hearing. Her early work on cochlear function and hair cell degeneration in the mutant deafness mouse led to identification of the gene called Tmc1, the human homologue of which is mutated in several forms of hereditary deafness. She and her colleagues went on to identify causative genes in nearly 30 forms of hearing disorder in mice, most of which have been linked to human conditions. In particular, she described the genes for myosin-7a and cadherin-23, which are key components in the transduction mechanism in hair cells, and mutations of which underlie forms of Usher Syndrome. Karen Steel is internationally recognized for her generous and altruistic approach to science. Working with a consortium of European researchers, she has established, catalogued and made freely available to other researchers<br /> several hundred mouse mutant lines, which have facilitated research in several areas of neuroscience around the world.<br /> About the Brain Prize The Brain Prize - € 1 million is awarded by Grete Lundbeck European Brain Research Foundation, a charitable, non-profit organization.<br /> The Brain Prize is a personal prize awarded to one or more scientists who have distinguished themselves by an outstanding contribution to European neuroscience.<br /> For more information please contact:<br /> Kim Krogsgaard, MD, DMSc or Director Mobile: +45 2014 8384 Phone: +45 3917 8240 <a href="mailto:kk@thebrainprize.org">kk@thebrainprize.org</a><br /> Nils Axelsen, MD, DMsc Chairman Mobile: +45 40548646<br /> Grete Lundbeck European Brain Research Foundation Ole Maaløes Vej 3 2200 N Copenhagen<br /> Denmark<br /> www.thebrainprize.org</p><p><a href="http://biologictube.dk/photo/4959161/brain-prize-winners-2012-karen"><img src="http://biologictube.dk/4959050/4959161/221a778e8530641df57b207fd7d2b4ab/standard/download-1-thumbnail.jpg" width="600" height="338"/></a></p> BioLogicMedia Bjørn Christine Karen Petit Steel Vidø and brain daniel eugen-olsen frank jesper kim krogsgaard lone lundbeck neuroscience prize http://biologictube.dk/photo/3087746/kfc <p>Klinisk Forskningscenter er en tværfaglig afdeling, som yder støtte og vejledning til forskningsprojekter og forskere, samt udvikler de faglige og forskningsmæssige ressourcer på hospitalet.</p> <p>Klinisk Forskningscenter ledes af forskningschef Ove Andersen, som assisteres af<br /> stabschef Linda Andresen og fuldmægtig Mette Lindstrøm.<br /> Har du spørgsmål, er du velkommen til at tage kontakt.<br /> <br /> <br /> <br /> <br /> Klinisk Forskningscenter er en tværfaglig afdeling på Hvidovre hospital, som yder støte og vejledning til forskningsprojekter og forskere, samt udvikler de faglige og forskningsmæssige ressourcer på hospitalet.<br /> <br /> 

Klinisk Forskningscenter blev etableret i 1999 med en forskningschef og en mindre stab. Staben består i 2007 af 12 fast- og 26 fondsansatte, heraf er 12 Ph.d.-studerende. Endvidere er 10 prægraduate studerende tilknyttet afdelingen.

Formålet er at fremme hospitalets overordnede mål for forskning, sikre en optimal udnyttelse af kompetencer og ressourcer samt sikre sammenhæng i indsatsen. Styrken i forskningscentret er, at problemstillinger, der afdækkes under det kliniske arbejde, kan belyses i videnskabelige projekter, der trækker på centrets og hospitalets ekspertise og ressourcer. Forskningscentret koordinerer aktiviteterne i en række afdelinger med metodologisk sammenfald i forskningsopgaverne. Forskningscentret varetager selvstændigt eller i samarbejde med andre forskningsmiljøer på hospitalet nye forsknings- og udviklingsopgver af større art.

Klinisk Forskningscenter er karakteriseret ved en omfattende sundhedsvidenskabelig forskning, dels gennem egne projekter, dels ved deltagelse i andre afdelingers projekter. Forskningsaktiviteterne spænder fra grundvidenskabelig forskning og laboratorieforskning til randomiserede klinisk kontrollerede undersøgelser og forskning i pleje og omsorg. Medarbejderstaben tæller endvidere to biostatistikere, der bl.a. tilbyder statistisk bistand til hospitalets ansatte samt til samarbejdspartnere og efter forudgående aftale til rekvireret arbejde.

Det er Klinisk Forskningscenters mål at fastholde og udbygge den videnskabelige aktivitet.

Forskningscentret har opbygget en markant forskningsmæssig profil og vil være i front indenfor kernefelterne, der bl.a. indbefatter translationel forskning indenfor cancer, virologi og inflammation.

Uddannelsesfunktionen omfatter prægraduat undervisning af lægestuderende, biologistuderende, laborantelever samt postgraduat universitetsrelateret kursus- og undervisningsaktiviteter.

Mål for Klinisk Forskningscenter

Forskningscentret skal være i front indenfor molekylærbiologisk-immunologisk og virologisk forskning.
Forskningscentret skal kunne tiltrække de bedste forskere indenfor miljøet og være drivkraft for tværfaglig forskningsaktivitet.
Forskningscentret skal bidrage til at styrke netværksdannelse med såvel offentlige som private institutioner
Forskningscentret skal bidrage til synliggørelse af hospitalets forskningsaktivitet.
Der henvises iøvrigt til hjemmesiden :
‪<a href="http://www.hvidovrehospital.dk/menu/Afdelinger/Klinisk+Forskningscenter/‬">http://www.hvidovrehospital.dk/menu/Afdelinger/Klinisk+Forskningscenter/‬</a></p> <p>Produceret af BioLogicMedia.dk<br /> Optagelser af Bjørn Vidø, Jesper Eugen-Olsen og Journalist Hanne Stetting Duvå</p><p><a href="http://biologictube.dk/photo/3087746/kfc"><img src="http://biologictube.dk/1984079/3087746/f815e3dd878dca12ac44258f919fa64a/standard/download-1-thumbnail.jpg" width="600" height="338"/></a></p> http://biologictube.dk/photo/3087746 Tue, 30 Aug 2011 22:42:33 GMT KFC Klinisk Forskningscenter er en tværfaglig afdeling, som yder støtte og vejledning til forskningsprojekter og forskere, samt udvikler de faglige og forskningsmæssige ressourcer på hospitalet. Klinisk Forskningscenter ledes af forskningschef Ove Andersen, som assisteres af stabschef Linda Andresen og fuldmægtig Mette Lindstrøm. Har du spørgsmål, er du velkommen til at tage kontakt. Klinisk Forskningscenter er en tværfaglig afdeling på Hvidovre hospital, som yder støte og vejledning til forskningsprojekter og forskere, samt udvikler de faglige og forskningsmæssige ressourcer på hospitalet. 

Klinisk Forskningscenter blev etableret i 1999 med en forskningschef og en mindre stab. Staben består i 2007 af 12 fast- og 26 fondsansatte, heraf er 12 Ph.d.-studerende. Endvidere er 10 prægraduate studerende tilknyttet afdelingen.

Formålet er at fremme hospitalets overordnede mål for forskning, sikre en optimal udnyttelse af kompetencer og ressourcer samt sikre sammenhæng i indsatsen. Styrken i forskningscentret er, at problemstillinger, der afdækkes under det kliniske arbejde, kan belyses i videnskabelige projekter, der trækker på centrets og hospitalets ekspertise og ressourcer. Forskningscentret koordinerer aktiviteterne i en række afdelinger med metodologisk sammenfald i forskningsopgaverne. Forskningscentret varetager selvstændigt eller i samarbejde med andre forskningsmiljøer på hospitalet nye forsknings- og udviklingsopgver af større art.

Klinisk Forskningscenter er karakteriseret ved en omfattende sundhedsvidenskabelig forskning, dels gennem egne projekter, dels ved deltagelse i andre afdelingers projekter. Forskningsaktiviteterne spænder fra grundvidenskabelig forskning og laboratorieforskning til randomiserede klinisk kontrollerede undersøgelser og forskning i pleje og omsorg. Medarbejderstaben tæller endvidere to biostatistikere, der bl.a. tilbyder statistisk bistand til hospitalets ansatte samt til samarbejdspartnere og efter forudgående aftale til rekvireret arbejde.

Det er Klinisk Forskningscenters mål at fastholde og udbygge den videnskabelige aktivitet.

Forskningscentret har opbygget en markant forskningsmæssig profil og vil være i front indenfor kernefelterne, der bl.a. indbefatter translationel forskning indenfor cancer, virologi og inflammation.

Uddannelsesfunktionen omfatter prægraduat undervisning af lægestuderende, biologistuderende, laborantelever samt postgraduat universitetsrelateret kursus- og undervisningsaktiviteter.

Mål for Klinisk Forskningscenter

Forskningscentret skal være i front indenfor molekylærbiologisk-immunologisk og virologisk forskning.
Forskningscentret skal kunne tiltrække de bedste forskere indenfor miljøet og være drivkraft for tværfaglig forskningsaktivitet.
Forskningscentret skal bidrage til at styrke netværksdannelse med såvel offentlige som private institutioner
Forskningscentret skal bidrage til synliggørelse af hospitalets forskningsaktivitet.
Der henvises iøvrigt til hjemmesiden :
‪http://www.hvidovrehospital.dk/menu/Afdelinger/Klinisk+Forskningscenter/‬ Produceret af BioLogicMedia.dk Optagelser af Bjørn Vidø, Jesper Eugen-Olsen og Journalist Hanne Stetting Duvå Klinisk Forskningscenter er en tværfaglig afdeling, som yder støtte og vejledning til forskningsprojekter og forskere, samt udvikler de faglige og forskningsmæssige ressourcer på hospitalet. Klinisk Forskningscenter ledes af forskningschef Ove... Welcome to the BioLogicTube 02:43 <p>Klinisk Forskningscenter er en tværfaglig afdeling, som yder støtte og vejledning til forskningsprojekter og forskere, samt udvikler de faglige og forskningsmæssige ressourcer på hospitalet.</p> <p>Klinisk Forskningscenter ledes af forskningschef Ove Andersen, som assisteres af<br /> stabschef Linda Andresen og fuldmægtig Mette Lindstrøm.<br /> Har du spørgsmål, er du velkommen til at tage kontakt.<br /> <br /> <br /> <br /> <br /> Klinisk Forskningscenter er en tværfaglig afdeling på Hvidovre hospital, som yder støte og vejledning til forskningsprojekter og forskere, samt udvikler de faglige og forskningsmæssige ressourcer på hospitalet.<br /> <br /> 

Klinisk Forskningscenter blev etableret i 1999 med en forskningschef og en mindre stab. Staben består i 2007 af 12 fast- og 26 fondsansatte, heraf er 12 Ph.d.-studerende. Endvidere er 10 prægraduate studerende tilknyttet afdelingen.

Formålet er at fremme hospitalets overordnede mål for forskning, sikre en optimal udnyttelse af kompetencer og ressourcer samt sikre sammenhæng i indsatsen. Styrken i forskningscentret er, at problemstillinger, der afdækkes under det kliniske arbejde, kan belyses i videnskabelige projekter, der trækker på centrets og hospitalets ekspertise og ressourcer. Forskningscentret koordinerer aktiviteterne i en række afdelinger med metodologisk sammenfald i forskningsopgaverne. Forskningscentret varetager selvstændigt eller i samarbejde med andre forskningsmiljøer på hospitalet nye forsknings- og udviklingsopgver af større art.

Klinisk Forskningscenter er karakteriseret ved en omfattende sundhedsvidenskabelig forskning, dels gennem egne projekter, dels ved deltagelse i andre afdelingers projekter. Forskningsaktiviteterne spænder fra grundvidenskabelig forskning og laboratorieforskning til randomiserede klinisk kontrollerede undersøgelser og forskning i pleje og omsorg. Medarbejderstaben tæller endvidere to biostatistikere, der bl.a. tilbyder statistisk bistand til hospitalets ansatte samt til samarbejdspartnere og efter forudgående aftale til rekvireret arbejde.

Det er Klinisk Forskningscenters mål at fastholde og udbygge den videnskabelige aktivitet.

Forskningscentret har opbygget en markant forskningsmæssig profil og vil være i front indenfor kernefelterne, der bl.a. indbefatter translationel forskning indenfor cancer, virologi og inflammation.

Uddannelsesfunktionen omfatter prægraduat undervisning af lægestuderende, biologistuderende, laborantelever samt postgraduat universitetsrelateret kursus- og undervisningsaktiviteter.

Mål for Klinisk Forskningscenter

Forskningscentret skal være i front indenfor molekylærbiologisk-immunologisk og virologisk forskning.
Forskningscentret skal kunne tiltrække de bedste forskere indenfor miljøet og være drivkraft for tværfaglig forskningsaktivitet.
Forskningscentret skal bidrage til at styrke netværksdannelse med såvel offentlige som private institutioner
Forskningscentret skal bidrage til synliggørelse af hospitalets forskningsaktivitet.
Der henvises iøvrigt til hjemmesiden :
‪<a href="http://www.hvidovrehospital.dk/menu/Afdelinger/Klinisk+Forskningscenter/‬">http://www.hvidovrehospital.dk/menu/Afdelinger/Klinisk+Forskningscenter/‬</a></p> <p>Produceret af BioLogicMedia.dk<br /> Optagelser af Bjørn Vidø, Jesper Eugen-Olsen og Journalist Hanne Stetting Duvå</p><p><a href="http://biologictube.dk/photo/3087746/kfc"><img src="http://biologictube.dk/1984079/3087746/f815e3dd878dca12ac44258f919fa64a/standard/download-1-thumbnail.jpg" width="600" height="338"/></a></p> BioLogic Bjørn Duvå Eugen-Olsen Forskningscenter Hanne Hvidovre Jesper Journalist Klinisk Media Stetting Vidø hospital http://biologictube.dk/photo/3085965/biologicmedia-showreel-spring <p>Communicating Life Science</p> <p>BioLogicMedia's culture and actions<br /> are designed to support our central<br /> goals which are communicating you,<br /> your product, your science and your<br /> story, and working with you and your<br /> team to create comprehendible,<br /> accurate and inspirational movie.<br /> We invite you to explore our work<br /> and we look forward to tell your story.</p> <p>With medical expertise, creative individuals and complete in-house<br /> high-end film production, the company<br /> can participate in all stages from the<br /> birth of concepts and ideas to the execution and delivery of end-stage products.<br /> <br /> <br /> Jesper Eugen-Olsen<br /> Scientific director of BioLogicMedia. 15 years of experience in medical research, virology, biomarkers, inflammation. Author or coauthor of more than 65 peer reviewed papers and 12 issued patents. Experience in entrepreneurship and business development. Founder/cofounder of ViroGates, IMMUTELL, EYEAMTV and BioLogicMedia. PhD from University of Copenhagen 2003. Specialties: Immunology, inflammation, biomarkers, patents and scientific communication.</p> <p>Bjørn Vidø<br /> Creative Director and cofounder of BioLogicMedia.<br /> 17 years of experience with Feature movies, Documentaries and<br /> commercials.<br /> Educated from the The National Film School of Denmark as a Sound Designer 1997. Founder/cofounder of Freezone, Welcome Sound, EYEAMTV and BioLogicMedia.<br /> Specialties: Creativity on all levels from the first idea to the finished production.<br /> <br /> <br /> www.biologicmedia.dk/</p><p><a href="http://biologictube.dk/photo/3085965/biologicmedia-showreel-spring"><img src="http://biologictube.dk/1984074/3085965/47ba010ac04a87118ef421d603a77ef0/standard/download-1-thumbnail.jpg" width="600" height="338"/></a></p> http://biologictube.dk/photo/3085965 Tue, 30 Aug 2011 18:36:04 GMT BioLogicMedia Showreel Spring 2011 Communicating Life Science BioLogicMedia's culture and actions are designed to support our central goals which are communicating you, your product, your science and your story, and working with you and your team to create comprehendible, accurate and inspirational movie. We invite you to explore our work and we look forward to tell your story. With medical expertise, creative individuals and complete in-house high-end film production, the company can participate in all stages from the birth of concepts and ideas to the execution and delivery of end-stage products. Jesper Eugen-Olsen Scientific director of BioLogicMedia. 15 years of experience in medical research, virology, biomarkers, inflammation. Author or coauthor of more than 65 peer reviewed papers and 12 issued patents. Experience in entrepreneurship and business development. Founder/cofounder of ViroGates, IMMUTELL, EYEAMTV and BioLogicMedia. PhD from University of Copenhagen 2003. Specialties: Immunology, inflammation, biomarkers, patents and scientific communication. Bjørn Vidø Creative Director and cofounder of BioLogicMedia. 17 years of experience with Feature movies, Documentaries and commercials. Educated from the The National Film School of Denmark as a Sound Designer 1997. Founder/cofounder of Freezone, Welcome Sound, EYEAMTV and BioLogicMedia. Specialties: Creativity on all levels from the first idea to the finished production. www.biologicmedia.dk/ Communicating Life Science BioLogicMedia's culture and actions are designed to support our central goals which are communicating you, your product, your science and your story, and working with you and your team to create comprehendible, accurate... Welcome to the BioLogicTube 02:42 <p>Communicating Life Science</p> <p>BioLogicMedia's culture and actions<br /> are designed to support our central<br /> goals which are communicating you,<br /> your product, your science and your<br /> story, and working with you and your<br /> team to create comprehendible,<br /> accurate and inspirational movie.<br /> We invite you to explore our work<br /> and we look forward to tell your story.</p> <p>With medical expertise, creative individuals and complete in-house<br /> high-end film production, the company<br /> can participate in all stages from the<br /> birth of concepts and ideas to the execution and delivery of end-stage products.<br /> <br /> <br /> Jesper Eugen-Olsen<br /> Scientific director of BioLogicMedia. 15 years of experience in medical research, virology, biomarkers, inflammation. Author or coauthor of more than 65 peer reviewed papers and 12 issued patents. Experience in entrepreneurship and business development. Founder/cofounder of ViroGates, IMMUTELL, EYEAMTV and BioLogicMedia. PhD from University of Copenhagen 2003. Specialties: Immunology, inflammation, biomarkers, patents and scientific communication.</p> <p>Bjørn Vidø<br /> Creative Director and cofounder of BioLogicMedia.<br /> 17 years of experience with Feature movies, Documentaries and<br /> commercials.<br /> Educated from the The National Film School of Denmark as a Sound Designer 1997. Founder/cofounder of Freezone, Welcome Sound, EYEAMTV and BioLogicMedia.<br /> Specialties: Creativity on all levels from the first idea to the finished production.<br /> <br /> <br /> www.biologicmedia.dk/</p><p><a href="http://biologictube.dk/photo/3085965/biologicmedia-showreel-spring"><img src="http://biologictube.dk/1984074/3085965/47ba010ac04a87118ef421d603a77ef0/standard/download-1-thumbnail.jpg" width="600" height="338"/></a></p> BioLogicMedia Bjørn Eugen-Olsen Jesper Vidø http://biologictube.dk/photo/3012951/2nd-international-supar <p>2’nd International suPAR Symposium<br /> The 2nd International Conference on suPAR” was taking place in early spring 2011 at the Danish National Museum in Copenhagen.</p> <p>The 1st International conference on suPAR” in 2003 shared findings on suPAR as a marker of disease progression and survival in HIV and TB infected. Since then, suPAR has been broadly applied to a range of diseases and the same picture is emerging. An elevated suPAR is associated with a negative prognosis independent of disease. Even among the general population, an elevated suPAR has recently been shown to be associated with increased risk of diseases such as cardiovascular disease, cancer and Type 2 Diabetes.</p> <p>But what does an elevated suPAR reflect? The suPAR level is positively correlated with markers of inflammation and immune activation such as CRP (hsCRP), TNF-a and white blood cell counts. Thus, suPAR may be a novel marker of inflammation, and increased inflammation has in recent years been suggested as a disease driving mechanism. Nevertheless, suPAR remains associated with disease endpoints after the adjustment of other inflammatory markers and is less related to metabolic variables than CRP. Thus suPAR may reflect another aspect of inflammation than the classical markers do.</p> <p>A large number of studies are currently investigating the role of suPAR in a wide variety of conditions, and this conference will bring forward the newest data which will further enlighten the role and possible applications of this biomarker.<br /> <br /> <br /> Purpose and Scope</p> <p>The suPAR (soluble urokinase Plasminogen Activator Receptor) protein is a relatively new biomarker which has ability to predict severity of illness and mortality. The prognostic value of suPAR has been described in published studies in recent years and is currently being tested in several health care applications.</p> <p>The symposium aim is to bring together researchers, users and other persons to discuss  the features and potential usability of the suPAR protein as a biomarker and will:<br /> <br /> ◦ Provide a forum to learn about new findings and current suPAR studies<br /> ◦ Host a scientific community discussion on the new opportunities that exist with a prognostic biomarker<br /> ◦ Hear from the delegates what questions, feed-back and ideas for suPAR applications and user requirements <br /> ◦ Facilitate foundation for international net-working</p> <p>Preliminary Agenda<br /> <br /> ◦ Session 1: suPAR and 10-year risk in the General Population<br /> ◦ Session 2: suPAR and Prognosis in Infectious Diseases<br /> ◦ Session 3: suPAR as a Risk Biomarker in the Intensive Care Unit<br /> ◦ Session 4: Decreasing suPAR Concentration – Impact on survival?<br /> ◦ Session 5: Is there a Role for suPAR in Disease Risk Management?<br /> ◦</p><p><a href="http://biologictube.dk/photo/3012951/2nd-international-supar"><img src="http://biologictube.dk/1984083/3012951/4cfe41cc55f5f4997ffd6d816822666b/standard/download-1-thumbnail.jpg" width="600" height="338"/></a></p> http://biologictube.dk/photo/3012951 Wed, 24 Aug 2011 11:49:48 GMT 2´nd International suPAR Symposium 2’nd International suPAR Symposium The 2nd International Conference on suPAR” was taking place in early spring 2011 at the Danish National Museum in Copenhagen. The 1st International conference on suPAR” in 2003 shared findings on suPAR as a marker of disease progression and survival in HIV and TB infected. Since then, suPAR has been broadly applied to a range of diseases and the same picture is emerging. An elevated suPAR is associated with a negative prognosis independent of disease. Even among the general population, an elevated suPAR has recently been shown to be associated with increased risk of diseases such as cardiovascular disease, cancer and Type 2 Diabetes. But what does an elevated suPAR reflect? The suPAR level is positively correlated with markers of inflammation and immune activation such as CRP (hsCRP), TNF-a and white blood cell counts. Thus, suPAR may be a novel marker of inflammation, and increased inflammation has in recent years been suggested as a disease driving mechanism. Nevertheless, suPAR remains associated with disease endpoints after the adjustment of other inflammatory markers and is less related to metabolic variables than CRP. Thus suPAR may reflect another aspect of inflammation than the classical markers do. A large number of studies are currently investigating the role of suPAR in a wide variety of conditions, and this conference will bring forward the newest data which will further enlighten the role and possible applications of this biomarker. Purpose and Scope The suPAR (soluble urokinase Plasminogen Activator Receptor) protein is a relatively new biomarker which has ability to predict severity of illness and mortality. The prognostic value of suPAR has been described in published studies in recent years and is currently being tested in several health care applications. The symposium aim is to bring together researchers, users and other persons to discuss  the features and potential usability of the suPAR protein as a biomarker and will: ◦ Provide a forum to learn about new findings and current suPAR studies ◦ Host a scientific community discussion on the new opportunities that exist with a prognostic biomarker ◦ Hear from the delegates what questions, feed-back and ideas for suPAR applications and user requirements  ◦ Facilitate foundation for international net-working Preliminary Agenda ◦ Session 1: suPAR and 10-year risk in the General Population ◦ Session 2: suPAR and Prognosis in Infectious Diseases ◦ Session 3: suPAR as a Risk Biomarker in the Intensive Care Unit ◦ Session 4: Decreasing suPAR Concentration – Impact on survival? ◦ Session 5: Is there a Role for suPAR in Disease Risk Management? ◦ 2’nd International suPAR Symposium The 2nd International Conference on suPAR” was taking place in early spring 2011 at the Danish National Museum in Copenhagen. The 1st International conference on suPAR” in 2003 shared findings on suPAR as a... Welcome to the BioLogicTube 01:27 <p>2’nd International suPAR Symposium<br /> The 2nd International Conference on suPAR” was taking place in early spring 2011 at the Danish National Museum in Copenhagen.</p> <p>The 1st International conference on suPAR” in 2003 shared findings on suPAR as a marker of disease progression and survival in HIV and TB infected. Since then, suPAR has been broadly applied to a range of diseases and the same picture is emerging. An elevated suPAR is associated with a negative prognosis independent of disease. Even among the general population, an elevated suPAR has recently been shown to be associated with increased risk of diseases such as cardiovascular disease, cancer and Type 2 Diabetes.</p> <p>But what does an elevated suPAR reflect? The suPAR level is positively correlated with markers of inflammation and immune activation such as CRP (hsCRP), TNF-a and white blood cell counts. Thus, suPAR may be a novel marker of inflammation, and increased inflammation has in recent years been suggested as a disease driving mechanism. Nevertheless, suPAR remains associated with disease endpoints after the adjustment of other inflammatory markers and is less related to metabolic variables than CRP. Thus suPAR may reflect another aspect of inflammation than the classical markers do.</p> <p>A large number of studies are currently investigating the role of suPAR in a wide variety of conditions, and this conference will bring forward the newest data which will further enlighten the role and possible applications of this biomarker.<br /> <br /> <br /> Purpose and Scope</p> <p>The suPAR (soluble urokinase Plasminogen Activator Receptor) protein is a relatively new biomarker which has ability to predict severity of illness and mortality. The prognostic value of suPAR has been described in published studies in recent years and is currently being tested in several health care applications.</p> <p>The symposium aim is to bring together researchers, users and other persons to discuss  the features and potential usability of the suPAR protein as a biomarker and will:<br /> <br /> ◦ Provide a forum to learn about new findings and current suPAR studies<br /> ◦ Host a scientific community discussion on the new opportunities that exist with a prognostic biomarker<br /> ◦ Hear from the delegates what questions, feed-back and ideas for suPAR applications and user requirements <br /> ◦ Facilitate foundation for international net-working</p> <p>Preliminary Agenda<br /> <br /> ◦ Session 1: suPAR and 10-year risk in the General Population<br /> ◦ Session 2: suPAR and Prognosis in Infectious Diseases<br /> ◦ Session 3: suPAR as a Risk Biomarker in the Intensive Care Unit<br /> ◦ Session 4: Decreasing suPAR Concentration – Impact on survival?<br /> ◦ Session 5: Is there a Role for suPAR in Disease Risk Management?<br /> ◦</p><p><a href="http://biologictube.dk/photo/3012951/2nd-international-supar"><img src="http://biologictube.dk/1984083/3012951/4cfe41cc55f5f4997ffd6d816822666b/standard/download-1-thumbnail.jpg" width="600" height="338"/></a></p> 2´nd Copenhagen. Eugen-Olsen International Jesper Symposium suPAR